HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- As genetic testing grows, individualized management of BRCA mutations urged
-
- Immunologic control measures may be key to reducing norovirus burden in HSCT recipients Herbert L. DuPont, MD, MACP
- USPSTF: Youth should be counseled against tobacco use
- Sirolimus-associated thrombotic microangiopathy develops after allogeneic transplant Tim McCarthy, MD
- First generic version of Xeloda approved for breast colorectal cancers
- Boxed warning for potential HBV reactivation added to Arzerra, Rituxan labeling
- FDA approves Perjeta for neoadjuvant breast cancer treatment
- Rapid DNA test for CYP2C19 variants receives FDA clearance
- FDA grants priority review for Tafinlar/Mekinist for melanoma
-
- ‘No compelling rationale’ to develop triplet regimen for recurrent, metastatic SCCHN
- Certain F8 mutations increased inhibitor formation in hemophilia A
- Rituximab prevented corticosteroid-requiring chronic GVHD
- Abiraterone acetate improved patient-reported quality of life
- Regimen recaptured responses in heavily pretreated multiple myeloma
- ADT linked to acute kidney injury risk in nonmetastatic prostate cancer
- Antiviral agent reduced cytomegalovirus disease after HSCT
- Biennial mammographic screening elevated false-positive risk
-
- Cabozantinib extended PFS in progressive, metastatic medullary thyroid cancer
- Cell vaccination early after transplant may increase T cells in CLL
- Cutaneous T-cell lymphoma incidence stabilized in US
- Docetaxel-cyclophosphamide plus trastuzumab effective in HER-2–amplified early breast cancer
- Endoscopic surveillance of Barrett’s esophagus patients does not improve cancer survival
- Ephrin B2 receptor could be therapeutic target for malignant mesothelioma
- Findings offer insights into mutational processes that lead to cancer development
- Genetic mutation identified in castration-resistant prostate cancer
-
- Genomic differences observed in cervical cancer subtypes
- Hormone therapy with, without chemotherapy linked to cognitive decline in early-stage breast cancer
- Hypofractionated radiotherapy safe, effective for early breast cancer
- Low-dose CT scan may predict early-stage lung cancer
- Low-dose aspirin use associated with reduced risk for colorectal cancer
- Mailed outreach improved colorectal cancer screening rates over standard care
- Neck dissection did not significantly affect regional control of larynx, hypopharynx cancers
- Obesity surgery associated with long-term risk for colorectal cancer
-
- Patients with HCC, SALL4 oncofetal gene require targeted therapy
- Patients with RA at increased risk for DVT, PE
- Pediatric-onset IBD increased cancer, not mortality risk
- Positive SLNB in thin melanomas predicted disease progression
- Proton therapy spared organs in children with neuroblastoma
- Purging peripheral blood stem cells did not extend survival in high-risk neuroblastoma
- Recent childbirth reduced OS in melanoma, breast cancer
- Reduction in colon cancer mortality greater for colonoscopy than sigmoidoscopy
-
- Report provides guidance for ordering vascular lab tests for venous system disorders
- Reprogrammed chemoresistant DLBCL cells responded to chemotherapy
- Risk stratification may guide hormone replacement therapy in breast cancer
- Single injection of rose bengal studied as melanoma treatment
- Umbilical cord blood transplantation improved juvenile myelomonocytic leukemia outcomes
- Dose-dense carboplatin/paclitaxel may become new standard for ovarian cancer
- Sepsis risk prediction tool assessed
- ASH announces grant recipients
-
- Cancer center fills leadership posts
- Mayo Clinic to open stem cell laboratory
- Radiation oncologist receives award
- Society members named fellows
- Three physicians join AACI board
- Sulfasalazine during, after pelvic radiation therapy may increase diarrhea risk
- Cediranib plus chemotherapy prolonged PFS, OS in ovarian cancer
- Biannual ultrasound cost-effective for HCC screening in cirrhotic patients
-
- Dermatologic side effects from sorafenib linked to better HCC survival
- Dermatologic side effects from sorafenib linked to better HCC survival
- Early response to TACE predictive of survival, extrahepatic metastasis
- HBV viremia linked to progression of dysplastic nodules to HCC
- Ipilimumab extended OS up to 10 years in patients with advanced melanoma
- No survival benefit from brivanib for patients with HCC
- Nodal radiation therapy improved breast cancer outcomes
- Progression-free HCC survival with sorafenib linked to low AFP, more adverse events
-
- Proton therapy effective for pediatric CNS ependymoma
- Radiation plus cisplatin improved DFS in patients with cervical cancer
- Radiofrequency ablation, hepatic resection similarly safe, effective for small HCC
- Treatment delay for HCC linked to increased mortality risk